Benchmarks ended Tuesday’s choppy trading session in the green led by gains from technology shares. Investors also remained focused on ECB’s meeting scheduled for Thursday. ECB is expected to unveil a bond-buying program in order to boost Eurozone’s economy. Investors also kept an eye on fourth-quarter earnings results of major companies including Halliburton, Baker Hughes, Johnson & Johnson, Morgan Stanley […]
Source: Flickr user epSos .de .There might not be a bell that will ring to alert investors when they have put their money in the wrong biotech stock, but there are warning signals that can help them avoid owning the most dangerous biotech companies. Our Motley Fool contributors explain what these warning signals are and how to use them to […]
You might want to invest in biotechnology, but be careful. It’s not an easy industry to master, and while some companies eventually skyrocket, many others flame out.One simple way to invest in biotech is the iShares Nasdaq Biotechnology ETF (Nasdaq: IBB), which is a fund of roughly 150 stocks that has grown by an annual average of almost 15 percent […]
This healthcare edition of Industry Focus takes a look at three biotech stocks and why each company is positioned for a great performance in the coming year.If your portfolio could use some exposure to healthcare and biotechs, join the Fool’s Michael Douglass and Todd Campbell, along with special guest Kristine Harjes, to learn more about three promising stocks in the […]
Few industries offer the promise and pitfalls of biotechnology. Clinical wins and losses can lead to extraordinary stock gains or falls that make the sector best suited for only the most risk-tolerant investor. However, for investors willing to take on that risk, our Motley Fool contributors believe these three biotech stocks could offer significant opportunities in the coming year.Brian Orelli […]
NASDAQ had a good surge last week, but now people are honestly wondering what’s next. It had a nice pop at the open yesterday,, but immediately headed south and stayed there for the rest of the session. The bad news was that there was no enthusiasm for buying, but the good news was that there was no real selling after […]
Source: Celgene Corp.The volatility that comes with investing in biotech stocks can test the patience of even the most risk-tolerant investor. Many investors may be better served focusing on companies with proven track records of success rather than concentrating on emerging biotech stocks that are more promise than profit. Fortunately, investing in proven performers doesn’t have to mean sacrificing growth! […]
NEW YORKThe stock market has gotten a bit more finicky over the past week, and that begs the question of whether or not investors could be in for a rocky start to 2015.If so, investors should be putting together their plans for handling a market drop now, rather than risk reacting poorly when the tape is tumbling. With that in […]
BioTime Harnesses Geron’s Stem Cell Technology And Its Founder; Is That Enough To Survive The Biotech Revolution?
By iCELL News on December 5, 2014 · Sector
by Ian CliftSummaryBioTime is a growing player in the anti-aging biotech revolution, buying up multiple assets, including Geron’s stem cell technology portfolio.Is buying time for biotechs the cliche in the BioTime name?BioTime is accumulating a large […]
The biotech industry has been absolutely soaring over the past two years, fueled by a rise in drug approvals, an merger-and-acquisition frenzy, and widespread reorganizations that have helped to mitigate the impact of the so-called “patent cliff.” Driving this point home, the closely watched iShares Nasdaq Biotechnology Index has appreciated a princely 162% since 2012:As earnings across the industry are […]
